Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Other financing activities (2017 - 2025)

Entera Bio has reported Other financing activities over the past 7 years, most recently at $1000.0 for Q3 2025.

  • For the quarter ending Q3 2025, Other financing activities changed N/A year-over-year to $1000.0, compared with a TTM value of $373000.0 through Dec 2025, up 15.48%, and an annual FY2025 reading of $262000.0, down 18.89% over the prior year.
  • Other financing activities came in at $1000.0 for Q3 2025, down from $186000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $105.8 million in Q3 2021 to a low of $1000.0 in Q3 2025.
  • Median Other financing activities over the past 3 years was $245000.0 (2024), compared with a mean of $36.3 million.
  • The sharpest move saw Other financing activities rose 25.89% in 2021, then soared 878.95% in 2025.
  • Over 3 years, Other financing activities stood at $105.8 million in 2021, then plummeted by 99.71% to $304000.0 in 2024, then plummeted by 99.67% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Other financing activities are $1000.0 (Q3 2025), $186000.0 (Q2 2025), and $186000.0 (Q1 2025).